Skip to main content
Premium Trial:

Request an Annual Quote

PathoQuest Raises $5M in Series B Round, Plans Clinical Trial of NGS-based Diagnostic

NEW YORK (GenomeWeb News) — PathoQuest, an infectious disease diagnostics startup based in Paris, has raised €3.8 million ($5 million) in a Series B private equity funding round, the company said today.

The firm, a 2010 spin-out from the Pasteur Institute and the Ecole Nationale Veterinaire d'Alfort, will use the funding for a clinical trial of a diagnostic assay it has been developing that combines next-generation sequencing and a cloud-based analysis software service.

PathoQuest's assay, which uses proprietary sample preparation and algorithms, will be able to identify pathogens in two days. The company plans to launch the assay commercially in 2015, utilizing a "software as a service" business model.

The clinical trial, which will compare the assay to current diagnostic approaches and will be conducted both in the US and the European Union, will focus on the diagnosis of severe multi-etiological infections in patients that are immuno-compromised because of an inherited disorder or because of treatment with immuno-suppressive drugs or cancer chemotherapy.

Existing investor Kurma Life Science Partners was joined by new investors Idinvest and Aurinvest in the latest funding round. The firm previously raised €2 million in 2011.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.